|
|
|
|
|
|
|
|
|
Webinar: Viral Vector for Rare and Ultra-rare Disease
|
Rare and ultra-rare disease programs require viral vector strategies tailored to smaller patient populations. Explore practical approaches to right-size development and manufacturing, determine appropriate scale, reduce costs and timelines, and align processes with clinical and commercial needs. This webinar will share practical strategies for leveraging manufacturing partners and advancing toward proof of concept and clinical validation efficiently and cost-effectively. Click here to learn more.
|
|
|
|
|
|
|
|
A conversation between Alexandra Strtak at BlueRock Therapeutics and Life Science Connect's Jon O'Connell
|
When measuring cell therapy potency, biochemical assays can provide a rapid alternative to the time- and material-consuming standard of cell-based assays.
|
|
|
|
|
|
|
|
|
|
What's The Greatest Risk For CDMOs Ahead?
|
|
Q&A | Vector BioMed
|
Economic volatility, regulatory uncertainty, and capacity constraints pose major risks to CDMOs, threatening growth, profitability, and long-term sustainability in an increasingly competitive global market.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
|
